Search

• Shionogi-ViiV Healthcare announces initial data from pivotal phase III study of dolutegravir in HIV

  Media

  SPRING-2 study meets primary endpoint of non-inferiority of dolutegravir compared to raltegravir over 48 weeks in treatment of HIV patients.

  https://www.gsk.com/en-gb/media/press-releases/shionogi-viiv-healthcare-announces-initial-data-from-pivotal-phase-iii-study-of-dolutegravir-in-hiv/

  First published: 02 April 2012

• ViiV Healthcare starts third phase III HIV treatment study investigating long-acting two-drug regimen of cabotegravir plus rilpivirine

  Media

  ViiV announced start of phase III study with a two-drug regimen of long-acting, injectable cabotegravir & rilpivirine in adults with HIV-1.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-starts-third-phase-iii-hiv-treatment-study-investigating-long-acting-two-drug-regimen-of-cabotegravir-plus-rilpivirine/

  First published: 27 November 2017

• ViiV Healthcare launches eighth phase III study in two-drug regimen programme for HIV-1 treatment

  Media

  TANGO will seek to enrol approximately 550 adults with HIV-1, from clinical trial sites in North America, Europe, Australia, and Japan.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-launches-eighth-phase-iii-study-in-two-drug-regimen-programme-for-hiv-1-treatment/

  First published: 08 February 2018

• ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational “bNAb” with potential for long-acting HIV treatment and prevention

  Media

  ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational “bNAb”.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-exclusive-licensing-agreement-with-the-national-institutes-of-health-for-investigational-bnab-with-potential-for-long-acting-hiv-treatment-and-prevention/

  First published: 21 November 2019

• ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naïve Adults with HIV-1

  Media

  ViiV Healthcare today announced initial results from the Phase IIIb/IV FLAMINGO (ING114915) study.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-data-from-phase-iiibiv-study-of-dolutegravir-vs-darunavir-in-treatment-naïve-adults-with-hiv-1/

  First published: 12 September 2013

• ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing

  Media

  ViiV Healthcare presents positive 48-week data from phase III study

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-48-week-data-from-phase-iii-study-showing-every-two-month-regimen-of-investigational-long-acting/

  First published: 09 March 2020

• GSK enters agreement to obtain exclusive license for JNJ-3989 to expand the development of bepirovirsen

  Media

  GSK plc and Arrowhead Pharmaceuticals Inc. today announced that they have reached an agreement with Janssen Pharmaceuticals, Inc.

  https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-obtain-exclusive-license-for-jnj-3989/

  First published: 31 October 2023

• ViiV Healthcare announces phase II study results for first two drug, long-acting injectable regimen for HIV-1 treatment

  Media

  32 week maintenance data presented at CROI showed comparable viral suppression rates between injectable regimen and three drug oral regimen

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-phase-ii-study-results-for-first-two-drug-long-acting-injectable-regimen-for-hiv-1-treatment/

  First published: 23 February 2016

• Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV

  Media

  Shionogi-ViiV announced results received from Phase III SINGLE study of dolutegravir in treatment-naive adults with HIV-1.

  https://www.gsk.com/en-gb/media/press-releases/shionogi-viiv-healthcare-announces-positive-initial-data-from-phase-iii-study-of-dolutegravir-based-regimen-vs-atripla-in-hiv/

  First published: 11 July 2012

• GSK presents phase III results for eltrombopag in hepatitis C virus related thrombocytopenia

  Media

  Full results from ENABLE 1 & 2 presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases

  https://www.gsk.com/en-gb/media/press-releases/gsk-presents-phase-iii-results-for-eltrombopag-in-hepatitis-c-virus-related-thrombocytopenia/

  First published: 07 November 2011